Vaxart Future Growth
Future criteria checks 2/6
Vaxart is forecast to grow earnings and revenue by 22.6% and 45.2% per annum respectively while EPS is expected to grow by 12.7% per annum.
Key information
22.6%
Earnings growth rate
12.7%
EPS growth rate
| Biotechs earnings growth | 42.4% |
| Revenue growth rate | 45.2% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 19 Nov 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 38 | -96 | -66 | -89 | 4 |
| 12/31/2025 | 30 | -89 | -58 | -76 | 4 |
| 12/31/2024 | 34 | -77 | -63 | -68 | 3 |
| 9/30/2024 | 17 | -72 | -51 | -51 | N/A |
| 6/30/2024 | 14 | -76 | -62 | -62 | N/A |
| 3/31/2024 | 9 | -82 | -68 | -67 | N/A |
| 12/31/2023 | 7 | -82 | -72 | -70 | N/A |
| 9/30/2023 | 4 | -89 | -92 | -86 | N/A |
| 6/30/2023 | 2 | -101 | -93 | -86 | N/A |
| 3/31/2023 | 1 | -108 | -104 | -94 | N/A |
| 12/31/2022 | 0 | -108 | -104 | -95 | N/A |
| 9/30/2022 | 0 | -105 | -88 | -81 | N/A |
| 6/30/2022 | 0 | -93 | -87 | -81 | N/A |
| 3/31/2022 | 0 | -80 | -74 | -68 | N/A |
| 12/31/2021 | 1 | -70 | -65 | -60 | N/A |
| 9/30/2021 | 1 | -64 | -60 | -55 | N/A |
| 6/30/2021 | 1 | -54 | -54 | -50 | N/A |
| 3/31/2021 | 2 | -47 | -39 | -37 | N/A |
| 12/31/2020 | 4 | -32 | -25 | -24 | N/A |
| 9/30/2020 | 8 | -25 | -17 | -17 | N/A |
| 6/30/2020 | 8 | -22 | -12 | -12 | N/A |
| 3/31/2020 | 7 | -19 | -12 | -12 | N/A |
| 12/31/2019 | 10 | -19 | -14 | -13 | N/A |
| 9/30/2019 | 8 | -17 | -16 | -15 | N/A |
| 6/30/2019 | 8 | -18 | -17 | -16 | N/A |
| 3/31/2019 | 8 | -22 | -10 | -9 | N/A |
| 12/31/2018 | 4 | -18 | -15 | -15 | N/A |
| 9/30/2018 | 3 | -15 | -12 | -11 | N/A |
| 6/30/2018 | 4 | -12 | N/A | -8 | N/A |
| 3/31/2018 | 5 | -7 | N/A | -16 | N/A |
| 12/31/2017 | 6 | -12 | N/A | -10 | N/A |
| 9/30/2017 | 9 | -16 | N/A | -9 | N/A |
| 12/31/2016 | 8 | -19 | N/A | -12 | N/A |
| 12/31/2015 | 0 | -22 | N/A | -15 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NB11 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: NB11 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: NB11 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: NB11's revenue (45.2% per year) is forecast to grow faster than the German market (5.7% per year).
High Growth Revenue: NB11's revenue (45.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if NB11's Return on Equity is forecast to be high in 3 years time